12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ramucirumab: Final Phase II data

Final data from an open-label Phase II trial in 40 patients with advanced NSCLC showed that first-line treatment with 10 mg/kg ramucirumab plus paclitaxel and carboplatin on day 1 of a 3-week cycle for up to 6 cycles led to a median PFS of 7.9 months and a 6-month...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >